ASBM is urging Congress to pass the SAFE Drugs Act of 2026, legislation designed to strengthen oversight of unsafe, unapproved, and mass-marketed copycat medicines. Pharmacy compounding plays an important and legitimate role in patient care when FDA-approved therapies are unavailable or when a patient has a specific clinical need that cannot be met by an approved product. However, in recent years, some large-scale compounding operations have expanded into interstate distribution of products that closely replicate commercially available, FDA-approved drugs—without undergoing the rigorous FDA review, inspection, and approval standards that protect public health. Patients deserve to know that the medicines they receive are what they claim to be—and that they have been made under appropriate safeguards. CLICK HERE to tell your Senators and Representative to support the SAFE Drugs Act. Read ASBM’s letter supporting the SAFE Drugs Act of 2026 here.